Search

Displaying results 4911 - 4920 of 6835 in total
  1. Drug

    KB3305

    go.drugbank.com/drugs/DB06349
    Experimental

    KB3305 is an investigational liver selective antagonist for the glucocorticoid receptor, developed by Karo Bio for the treatment of Type 2 Diabetes.

  2. Drug

    OMS906

    go.drugbank.com/drugs/DB17722
    Investigational

    OMS906 is a humanized Igg4 monoclonal antibody against mannan-binding lectin-associated serine protease-3 (MASP-3) currently being developed by Omeros.

  3. Drug

    Seliforant

    go.drugbank.com/drugs/DB15220
    Investigational

    Seliforant is under investigation in clinical trial NCT01260753 (Proof of Activity Study of UR-63325 in Allergic Rhinitis Induced by Nasal Challenge).

  4. Drug

    NS-2359

    go.drugbank.com/drugs/DB05805
    Investigational

    NS2359 is a triple monoamine re-uptake inhibitor with a new, unique drug profile expected to yield important benefits compared to existing treatments of depression. … This mode of action is expected to produce an optimal reduction in all disease symptoms and the possibility of an earlier onset of action compared to antidepressants already on the market.

  5. Drug

    RGX-121

    go.drugbank.com/drugs/DB17681
    Investigational

    RGX-121 is designed to use the NAV AAV9 vector to deliver the human iduronate-2-sulfatase gene to the central nervous system.

  6. Drug

    XL844

    go.drugbank.com/drugs/DB05149
    Investigational

    XL844 is a potent inhibitor of the checkpoint kinases CHK1 and CHK2, which induce cell cycle arrest in response to a variety of DNA damaging agents.

  7. Drug

    Fosinoprilat

    go.drugbank.com/drugs/DB14207
    Experimental

    Fosinoprilat is the active phosphinic acid metabolite of prodrug [fosinopril], which is activated by esterases in vivo. It binds zinc with phosphinic acid group.

  8. Drug

    GLP-1 (7-36) amide

    go.drugbank.com/drugs/DB19258
    Investigational

    GLP-1 (7-36) amide is under investigation in clinical trial NCT01185119 (Effect of GLP-1 on Glucose Metabolism in CNS Assessed by PET).

  9. Drug

    AG0302-COVID19

    go.drugbank.com/drugs/DB16435
    Investigational

    Sponsored by Anges, Inc. in Japan, the AG0302-COVID19 is a DNA-based vaccine that recently completed Phase I/II trials (NCT04527081)[A226813, L30548].

  10. Drug

    VAD-044

    go.drugbank.com/drugs/DB17697
    Investigational

    VAD-044 is an allosteric AKT inhibitor developed by Vaderis Therapeutics AG. It is being investigated for the treatment of Hereditary Hemorrhagic Telangiectasia.[L46098]